Analysis of fatty acid profiles of micronutrients and pharmaceuticals based on omega-3 polyunsaturated fatty acid extracts from natural sources
Background. Omega-3 polyunsaturated fatty acids (ω3-PUFA) are an important factor in somatic and reproductive health. Micronutrient and pharmaceutical preparations based on ω3-PUFA are widely used for cardioprotection (prevention of atherosclerosis, endothelial dysfunction, chronic inflammation, exc...
Saved in:
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
IRBIS LLC
2023-09-01
|
| Series: | Фармакоэкономика |
| Subjects: | |
| Online Access: | https://www.pharmacoeconomics.ru/jour/article/view/1205 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| Summary: | Background. Omega-3 polyunsaturated fatty acids (ω3-PUFA) are an important factor in somatic and reproductive health. Micronutrient and pharmaceutical preparations based on ω3-PUFA are widely used for cardioprotection (prevention of atherosclerosis, endothelial dysfunction, chronic inflammation, excessive thrombus formation), support of reproductive function during pregnancy and improvement of neurological development of children. The effectiveness of ω3-PUFA preparations is determined by their fatty acid composition: the amounts of eicosapentaenoic acid (EPA), docosahexaenoic acid (DHA) and other types of unsaturated and saturated fatty acids.Objective: To analyze the fatty acid composition of micronutrient and pharmaceutical preparations of ω3-PUFA.Material and methods. The fatty acid composition of 16 ω3-PUFA preparations was studied. The method of quantitative chromatographic determination of more than 50 fatty acids, their derivatives and other compounds was used.Results. Previously obtained pharmacomarkers of fatty acid composition were confirmed and new ones were obtained, allowing with high reliability to separate drugs with a high degree of standardization for ω3-PUFA (Omacor®, NFO Omega-3 Premium®, NFO® Omega-3 Strong DHA, NFO® Omega-3 Ultima, etc.) from less standardized drugs (Fish oil-Teva®, Omeganol®, etc.). New, more effective criteria for assessing the quality of the fatty acid composition of ω3-PUFA drugs were proposed. In particular, the feasibility of the criteria "ω11<3%", "EPA+DHA>55%" corresponds to more standardized drugs with better purification quality. The usefulness of our proposed "standardization coefficient" of preparations, assessing the compliance of measured ω3-PUFA levels with the content declared by the manufacturer, has been confirmed.Conclusion. The feasibility of the criteria “ω11<3%”, “EPA+DHA>55%” corresponds to more standardized preparations. Preparations with a very high degree of standardization for ω3-PUFA (NFO® Omega-3 Ultima, NFO® Omega-3 Strong DHA, Omacor®) have been identified. The identification of highly standardized preparations allows physicians and patients to make informed choices when considering ω3-PUFA supplementation. |
|---|---|
| ISSN: | 2070-4909 2070-4933 |